靶向NAMPT在高危儿童急性淋巴细胞白血病人源异种移植模型中有效
研究评估新型NAMPT抑制剂OT-82对高危儿童急性淋巴细胞白血病(ALL)人源异种移植(PDX)模型的疗效。OT-82单药耐受良好,在95%(20/21)的PDX中显著延缓白血病生长,在86%(18/21)中诱导疾病消退,并增强阿糖胞苷和达沙替尼的疗效。其作用机制涉及耗竭NAD+和ATP、抑制PARP-1、增加线粒体ROS、诱导DNA损伤和凋亡。
要点
- OT-82单药在95%(20/21)高危儿童ALL PDX中显著延缓白血病生长。
- OT-82在86%(18/21)PDX中诱导疾病消退,耐受良好。
- OT-82增强阿糖胞苷和达沙替尼疗效,单药疗效与三药诱导方案相似。
核心结论
- OT-82单药或与现有药物联合是广谱高危儿童ALL的有前景新治疗策略。
研究设计与样本
- 研究使用来自高危和预后不良儿童ALL病例的一组人源异种移植(PDX)模型评估OT-82的疗效。
主要发现
- OT-82单药在95%(20/21)的PDX中实现显著白血病生长延迟,在86%(18/21)中实现疾病消退。
- OT-82增强阿糖胞苷和达沙替尼的疗效,单药疗效与用于儿童ALL的三药诱导方案相似。
- OT-82通过耗竭NAD+和ATP、抑制PARP-1、增加线粒体ROS水平、诱导DNA损伤并最终引起凋亡发挥抗白血病作用。
- OT-82敏感性与主要DNA损伤反应基因突变相关,耐药性以CD38高表达为特征。
临床怎么用
- OT-82可作为高危儿童ALL的潜在单药或联合治疗选择,尤其适用于DNA损伤反应基因突变者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis for children diagnosed with high-risk acute lymphoblastic leukemia (ALL) remains suboptimal, and more potent and less toxic treatments are urgently needed. We investigated the efficacy of a novel nicotinamide phosphoribosyltransferase inhibitor, OT-82, against a panel of patient-derived xenografts (PDXs) established from high-risk and poor outcome pediatric ALL cases. OT-82 was well-tolerated and demonstrated impressive single agent in vivo efficacy, achieving significant leukemia growth delay in 95% (20/21) and disease regression in 86% (18/21) of PDXs. In addition, OT-82 enhanced the efficacy of the established drugs cytarabine and dasatinib and, as a single agent, showed similar efficacy as an induction-type regimen combining three drugs used to treat pediatric ALL. OT-82 exerted its antileukemic action by depleting NAD+ and ATP, inhibiting the NAD+-requiring DNA damage repair enzyme PARP-1, increasing mitochondrial ROS levels and inducing DNA damage, culminating in apoptosis induction. OT-82 sensitivity was associated with the occurrence of mutations in major DNA damage response genes, while OT-82 resistance was characterized by high expression levels of CD38. In conclusion, our study provides evidence that OT-82, as a single agent, and in combination with established drugs, is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric ALL for which improved therapies are urgently needed.
引用
- Somers K, Evans K, Cheung L, et al. Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia. 2019. PMID: 31848452. doi:10.1038/s41375-019-0683-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。